Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 4/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.32 |
| ▸ | MAP4K1 | Q92918 | 4/20 | 0.32 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.30 |
| ▸ | PTGES | O14684 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4097527 | 0.91 | CRHR1 (0.34) | CRHR1MAP4K1AURKAAURKB | |
| SCHEMBL4100834 | 0.91 | CRHR1 (0.36) | CRHR1PDE4BHCRTR1HCRTR2MAP4K1 | |
| SCHEMBL4102631 | 0.87 | MAP4K1 (0.36) | CRHR1MAP4K1ROCK2ROCK1AURKA | |
| SCHEMBL4109662 | 0.86 | MAP4K1 (0.33) | CRHR1MAP4K1AURKAAURKB | |
| SCHEMBL4096426 | 0.84 | CRHR1 (0.36) | CRHR1MAP4K1AURKAAURKBPTGES | |
| SCHEMBL4091392 | 0.82 | AURKA (0.33) | CRHR1MAP4K1ROCK2ROCK1AURKA | |
| SCHEMBL4091530 | 0.82 | MAP4K1 (0.38) | CRHR1PDE4BMAP4K1ROCK2ROCK1 | |
| SCHEMBL4091434 | 0.82 | AURKA (0.36) | CRHR1PDE4BMAP4K1ROCK2ROCK1 | |
| SCHEMBL4107211 | 0.81 | MAP4K1 (0.34) | CRHR1MAP4K1ROCK2ROCK1AURKA | |
| SCHEMBL4096030 | 0.81 | AURKA (0.36) | CRHR1PDE4BMAP4K1AURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090234117-A1 | Pyrazolopyrimidine Derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1903045-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234117-A1 | Pyrazolopyrimidine Derivative | MC2R, CRHR1, AVPR2 | CRHR1 2/4885PDE4B 1164/4885HCRTR1 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.